Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca’s Stable Cash Runway and Upcoming Clinical Milestones Secure Buy Rating

Erasca reports Q1 results

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings

Erasca to Present at the Bank of America Health Care Conference

Erasca to Present at the Bank of America Health Care Conference

Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings

Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?

Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Best Momentum Stocks to Buy for April 23rd